X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Navitas Brings End-to-End R&D Solutions to the Generic Drug Industry

Yuvraj_pawp by Yuvraj_pawp
30th November 2017
in Research & Development

Navitas Life Sciences, a TAKE Solutions Enterprise, provides services and technology to deliver “first to file” results to generic drug companies around the globe, allowing them to bring affordable healthcare to more and more patients throughout the world. Navitas Life Sciences has conducted more than 1000 projects with over 100 Marketing Authorization Holders (MAH) approved in six continents. With over 50 generic and innovator pharma clients, Navitas Life Sciences has over 10 years of proven expertise.

Speed to market is critical, but quality and regulatory compliance can never be sacrificed. Navitas Life Sciences’ highly skilled team delivers uncompromised quality of the highest level, along with personalized services. Inspected by the FDA, WHO, Health Canada, EMA, DCGI, TGA & NPC, among other regulators, Navitas Life Sciences provides rapid set-up with tailored multi-analyte methods in 4-5 weeks. Certified to ISO 9001, ISO 27001, and ISO 15189, and accredited by CAP, Navitas Life Sciences has received ZERO observations in its last three FDA inspections.

Navitas Life Sciences also operates multiple study sites with a ready volunteer pool of over 20,000 including special groups, ICU access and 210 beds. Navitas’ full service includes medical writing, eCTD submission services or software, data standardization into company or CDISC standards, along with data archival allows clients to compete while avoiding the high cost of regulatory compliance for accelerated studies. Companies that lack internal capabilities in terms of studies or regulatory compliance, along with a need for ready access to hospital sites can benefit from the complete solution Navitas provides.

Generic drugs, low – cost copies of branded pharmaceutical drugs, have been gaining in volume and market share. Typically priced at significant discounts (50% – 90%) to their branded counterparts, health plans and governments around the world are encouraging and promoting the use of generic drugs. Once a branded drug’s patent has expired, any company can sell a generic version of that drug, but in the US, the FDA grants a 180-day exclusivity period to the company that is the first to market, or first to file. For a blockbuster drug (billion dollar a year seller) that exclusivity equates to $500 million.

Navitas Life Sciences harnesses the combined knowledge and experience of three legacy brands—Ecron Acunova, Navitas, and Intelent, to bring End – to End R&D solutions to the generic drug industry. With capabilities across BA/BE (Bioavailability/Bioequivalence) studies, clinical data management and pharmacovigilance software and services, Navitas Life Sciences presents global generic companies with a one stop shop of transformative offerings to enable a “first to market” advantage.

For more information, visit http://www.navitaslifesciences.com/ba-be-studies

About Navitas, Inc.
As a partner for the industry, Navitas Life Sciences leverages industry insights, consulting and technology capabilities to deliver full service clinical, regulatory and safety solutions and desired outcomes to clients. As the dedicated life sciences brand of TAKE Solutions, Navitas harnesses the combined knowledge and experience of three legacy brands—Ecron Acunova, Navitas, and Intelent—to provide end-to-end services and solutions. Navitas helps clients address their most critical problems by bringing together the capabilities of a full-service CRO, a technology-led life sciences services provider across clinical, regulatory and safety, and a life sciences big data services and analytics provider. Operating from seven countries across the globe, Navitas works with over 150 customers in the Life Sciences industry.

Media Contact:
Patrick Mullen
609-454-7753
186889@email4pr.com

Previous Post

Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary

Next Post

Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023
News

Randomness Drives Tumour Cells Response To Chemotherapy

10th March 2023
Featured

Animal Testing Could See An End With An Artificial Model

28th February 2023
Featured

Germany Rolls First CAR-T Push For Muscle Inflammation Cure

27th February 2023
Next Post

Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In